AVDL
Price
$19.23
Change
+$0.08 (+0.42%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
1.87B
116 days until earnings call
Intraday BUY SELL Signals
BCRX
Price
$6.91
Change
-$0.27 (-3.76%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
1.51B
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AVDL vs BCRX

Header iconAVDL vs BCRX Comparison
Open Charts AVDL vs BCRXBanner chart's image
Avadel Pharmaceuticals
Price$19.23
Change+$0.08 (+0.42%)
Volume$25.18K
Capitalization1.87B
BioCryst Pharmaceuticals
Price$6.91
Change-$0.27 (-3.76%)
Volume$132.61K
Capitalization1.51B
AVDL vs BCRX Comparison Chart in %
View a ticker or compare two or three
VS
AVDL vs. BCRX commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVDL is a Buy and BCRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (AVDL: $19.15 vs. BCRX: $7.18)
Brand notoriety: AVDL and BCRX are both notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AVDL: 81% vs. BCRX: 67%
Market capitalization -- AVDL: $1.88B vs. BCRX: $1.45B
AVDL [@Pharmaceuticals: Generic] is valued at $1.88B. BCRX’s [@Pharmaceuticals: Generic] market capitalization is $1.45B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVDL’s FA Score shows that 0 FA rating(s) are green whileBCRX’s FA Score has 1 green FA rating(s).

  • AVDL’s FA Score: 0 green, 5 red.
  • BCRX’s FA Score: 1 green, 4 red.
According to our system of comparison, AVDL is a better buy in the long-term than BCRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVDL’s TA Score shows that 5 TA indicator(s) are bullish while BCRX’s TA Score has 5 bullish TA indicator(s).

  • AVDL’s TA Score: 5 bullish, 5 bearish.
  • BCRX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, BCRX is a better buy in the short-term than AVDL.

Price Growth

AVDL (@Pharmaceuticals: Generic) experienced а +1.00% price change this week, while BCRX (@Pharmaceuticals: Generic) price change was +0.14% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.08%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +32.16%.

Reported Earning Dates

AVDL is expected to report earnings on Mar 09, 2026.

BCRX is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AVDL($1.87B) has a higher market cap than BCRX($1.51B). AVDL YTD gains are higher at: 82.207 vs. BCRX (-4.521). BCRX has higher annual earnings (EBITDA): 63.4M vs. AVDL (7.87M). BCRX has more cash in the bank: 260M vs. AVDL (81.5M). AVDL has less debt than BCRX: AVDL (2.73M) vs BCRX (703M). BCRX has higher revenues than AVDL: BCRX (558M) vs AVDL (221M).
AVDLBCRXAVDL / BCRX
Capitalization1.87B1.51B124%
EBITDA7.87M63.4M12%
Gain YTD82.207-4.521-1,818%
P/E RatioN/AN/A-
Revenue221M558M40%
Total Cash81.5M260M31%
Total Debt2.73M703M0%
FUNDAMENTALS RATINGS
AVDL vs BCRX: Fundamental Ratings
AVDL
BCRX
OUTLOOK RATING
1..100
346
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
33
Fair valued
PROFIT vs RISK RATING
1..100
4282
SMR RATING
1..100
92100
PRICE GROWTH RATING
1..100
3764
P/E GROWTH RATING
1..100
38100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (33) in the Biotechnology industry is somewhat better than the same rating for AVDL (82) in the Medical Specialties industry. This means that BCRX’s stock grew somewhat faster than AVDL’s over the last 12 months.

AVDL's Profit vs Risk Rating (42) in the Medical Specialties industry is somewhat better than the same rating for BCRX (82) in the Biotechnology industry. This means that AVDL’s stock grew somewhat faster than BCRX’s over the last 12 months.

AVDL's SMR Rating (92) in the Medical Specialties industry is in the same range as BCRX (100) in the Biotechnology industry. This means that AVDL’s stock grew similarly to BCRX’s over the last 12 months.

AVDL's Price Growth Rating (37) in the Medical Specialties industry is in the same range as BCRX (64) in the Biotechnology industry. This means that AVDL’s stock grew similarly to BCRX’s over the last 12 months.

AVDL's P/E Growth Rating (38) in the Medical Specialties industry is somewhat better than the same rating for BCRX (100) in the Biotechnology industry. This means that AVDL’s stock grew somewhat faster than BCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVDLBCRX
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 10 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
69%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
AVDL
Daily Signal:
Gain/Loss:
BCRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGPMX48.711.65
+3.51%
Franklin Gold and Precious Metals R6
EISVX31.590.21
+0.67%
Carillon ClariVest Intl Stock R6
AUERX16.810.07
+0.42%
Auer Growth
WFMIX50.170.12
+0.24%
Allspring Special Mid Cap Value Inst
GCPAX22.020.02
+0.09%
Gateway Equity Call Premium A

AVDL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVDL has been loosely correlated with RMTI. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if AVDL jumps, then RMTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVDL
1D Price
Change %
AVDL100%
+1.70%
RMTI - AVDL
35%
Loosely correlated
-9.04%
ELAN - AVDL
32%
Poorly correlated
-3.54%
BCRX - AVDL
29%
Poorly correlated
-0.69%
VTRS - AVDL
28%
Poorly correlated
-1.70%
EBS - AVDL
27%
Poorly correlated
-0.64%
More

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
-0.69%
VCYT - BCRX
46%
Loosely correlated
-0.84%
CRNX - BCRX
42%
Loosely correlated
-0.28%
HOWL - BCRX
39%
Loosely correlated
-3.54%
ROIV - BCRX
38%
Loosely correlated
+2.01%
BEAM - BCRX
38%
Loosely correlated
-2.71%
More